Overview

Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in 'severe' cirrhotic patients with large ascites. The primary outcome will be the 12-month survival.

Phase:

Phase 3

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Besancon

Collaborators:

Alfasigma S.p.A.
LC2 PHARMA

Treatments:

Rifamycins
Rifaximin